Kestra Medical Technologies (NASDAQ:KMTS) Sets New 12-Month Low - Should You Sell?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) shares reached a new 52-week low on Wednesday . The stock traded as low as $14.45 and last traded at $15.07, with a volume of 383439 shares traded. The stock had previously closed at $16.65.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KMTS. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $28.00 price objective on the stock. Wolfe Research started coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price objective for the company. Wells Fargo & Company assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set an "overweight" rating and a $28.00 target price for the company. Piper Sandler assumed coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price target on the stock. Finally, The Goldman Sachs Group lowered their price target on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.

Kestra Medical Technologies Trading Down 3.1%

The firm's fifty day simple moving average is $21.96.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings data on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter last year, the business earned ($1.18) EPS.

Institutional Trading of Kestra Medical Technologies

Several hedge funds have recently added to or reduced their stakes in KMTS. Brown Advisory Inc. bought a new position in Kestra Medical Technologies in the 1st quarter worth approximately $13,716,000. Caas Capital Management LP bought a new position in Kestra Medical Technologies in the 1st quarter worth approximately $1,470,000. Jennison Associates LLC bought a new position in Kestra Medical Technologies in the 1st quarter worth approximately $1,869,000. TD Asset Management Inc bought a new position in Kestra Medical Technologies in the 1st quarter worth approximately $2,306,000. Finally, Federated Hermes Inc. acquired a new position in shares of Kestra Medical Technologies during the first quarter valued at about $9,968,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.